ERBB2 and colorectal carcinoma: Identification and validation of predictive and/or prognostic biomarkers in CRC have revolutionized the management of the disease (BRAF, K-, N-RAS, and MSI), and others will also be used in the near future in clinical practice (HER2 and PD-1/PD-L1) [23].